Ilaprazole

Summary

Ilaprazole (CHEMBL2106370) is a phase-3 clinical-stage small molecule (ATC A02BC11) targeting ATP4A; indicated across 4 conditions including duodenal ulcer and gastroesophageal reflux disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A02BC11
• Targets: 1 (ATP4A)
• Indications: 4 conditions
• Clinical trials: 25
• Chemistry: 366.4 Da · C19H18N4O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2106370
Name	Ilaprazole
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	214351
ATC	A02BC11
Molecular formula	C19H18N4O2S
Molecular weight	366.4
InChIKey	HRRXCXABAPSOCP-UHFFFAOYSA-N

SMILES: CC1=C(C=CN=C1CS(=O)C2=NC3=C(N2)C=C(C=C3)N4C=CC=C4)OC

IUPAC name: 2-[(4-methoxy-3-methyl-2-pyridinyl)methylsulfinyl]-6-pyrrol-1-yl-1H-benzimidazole

Also known as: Ilaprazol, Ilaprazole, Noltec, ILAPRAZOLE

Patent coverage: 253 distinct patent families (568 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 457 (80%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ATP4A	ATP4A	Inhibition	8.05	0.2%	P20648

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): ATP4A.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Transport of small molecules	1	ATP4A
Ion transport by P-type ATPases	1	ATP4A
Ion channel transport	1	ATP4A

Dominant GO biological processes

GO term	Targets
intracellular sodium ion homeostasis	1
response to xenobiotic stimulus	1
regulation of proton transport	1
intracellular potassium ion homeostasis	1
monoatomic ion transmembrane transport	1
sodium ion export across plasma membrane	1
pH reduction	1
potassium ion transmembrane transport	1
proton transmembrane transport	1
potassium ion import across plasma membrane	1
monoatomic ion transport	1
potassium ion transport	1
establishment or maintenance of transmembrane electrochemical gradient	1

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
duodenal ulcer	3	MONDO:0005412	EFO:0004607
gastroesophageal reflux disease	3	MONDO:0007186	EFO:0003948
peptic ulcer disease	3	MONDO:0004247	HP:0004398

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
PHASE3	8
PHASE4	7
PHASE1	5
PHASE2	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02401477	PHASE4	COMPLETED	Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection
NCT02638584	PHASE4	COMPLETED	Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.
NCT02648659	PHASE4	COMPLETED	The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients
NCT02666976	PHASE4	COMPLETED	The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker
NCT02873065	PHASE4	COMPLETED	Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori
NCT03139253	PHASE4	UNKNOWN	Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
NCT03342456	PHASE4	COMPLETED	The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers
NCT06284876	PHASE3	RECRUITING	Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer
NCT00952978	PHASE3	COMPLETED	Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)
NCT01509261	PHASE3	COMPLETED	Efficacy Study of Ilaprazole to Treat Erosive Esophgitis
NCT02084420	PHASE3	COMPLETED	Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment
NCT02847455	PHASE2/PHASE3	COMPLETED	Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients
NCT02860624	PHASE3	COMPLETED	Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
NCT03362281	PHASE3	COMPLETED	Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
NCT03444883	PHASE3	COMPLETED	Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD
NCT05841394	PHASE3	COMPLETED	A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding
NCT00471094	PHASE2	COMPLETED	Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
NCT00953381	PHASE2	COMPLETED	Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)
NCT01107938	PHASE2	UNKNOWN	Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
NCT03362268	PHASE2	COMPLETED	IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
NCT01688544	PHASE1	COMPLETED	Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism
NCT01820143	PHASE1	COMPLETED	Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety
NCT02998437	PHASE1	COMPLETED	Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole
NCT05237297	PHASE1	COMPLETED	Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole
NCT05558150	PHASE1	COMPLETED	Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

5 molecules share ≥1 primary target. Top 5 by shared-target count:

Molecule	Source	Status	Shared targets
CIMETIDINE	ChEMBL + PubChem	Phase 4 (approved)	ATP4A
LANSOPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	ATP4A
PANTOPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	ATP4A
OMEPRAZOLE	ChEMBL	Phase 4 (approved)	ATP4A
RANITIDINE	ChEMBL	Phase 4 (approved)	ATP4A